Beyond the balloon: endoscopic duodenal therapy, the newest tool against diabetes and obesity

I've written before about endoscopic tools like the Orbera and Elipse gastric balloons and endoscopic sleeve gastroplasty (ESG) — procedures that use an endoscope, without any incisions, to help patients lose weight. There's a newer, conceptually different category of endoscopic therapy that patients increasingly ask me about, and it deserves its own explanation because it works through a completely different mechanism: it doesn't shrink the stomach at all. It targets the duodenum — the first segment of the small intestine — and it's aimed less at weight loss directly and more at resetting the body's metabolic and blood sugar control. This category is called duodenal mucosal resurfacing, or DMR.

The concept is rooted in an interesting piece of biology: the duodenum is one of the body's most important sites for nutrient sensing. It's lined with cells that detect incoming food and send signals that influence insulin sensitivity, appetite, and metabolic regulation throughout the body. In patients with long-standing obesity and type 2 diabetes, the lining of the duodenum appears to become thickened and metabolically abnormal — and there's growing evidence that this altered lining itself contributes to insulin resistance, not just a symptom of it. DMR works by gently ablating (removing) this superficial abnormal lining endoscopically, allowing healthy mucosa to regrow in its place over the following weeks, with the idea that the new lining "resets" some of this abnormal signaling.

There are currently three distinct techniques being studied. Hydrothermal DMR uses a balloon catheter to deliver heated water at about 80°C, ablating the duodenal lining for about 10 seconds per treated segment without damaging the deeper muscle layers. Laser duodenal ablation, using a device called the Digma System, uses a focused laser to treat about 6 cm of the duodenal circumference per cycle, up to a total of 24 cm. And irreversible electroporation (IRE) uses pulsed electrical fields, rather than heat, to trigger targeted cell death in 2 cm segments, treating up to 10 cm total. All three approaches are performed endoscopically, typically as outpatient or short-stay procedures, without incisions.

The results so far, while still early, are genuinely interesting from a glycemic-control standpoint. In studies combining hydrothermal DMR with liraglutide (an older GLP-1 medication), about 69% of patients maintained adequate blood sugar control at six months, and 53% remained free of insulin injections at 18 months — meaningful outcomes for patients trying to avoid or reduce insulin therapy. Data combining IRE with semaglutide showed 86% of patients avoided needing basal insulin at 12 months. I want to be clear about what this data does and doesn't show: weight loss with DMR alone tends to be modest and inconsistent across studies — this is not, at this stage, a weight-loss procedure comparable to a gastric balloon or ESG. Its more established signal is in improving insulin sensitivity and glycemic control, particularly as an add-on to GLP-1-based medication rather than a replacement for it. There is also early, still-investigational evidence of benefit for MASLD (fatty liver disease), through reduced liver fat, though this needs considerably more study.

Safety data remains reassuring but limited. Most reported side effects have been mild — nausea and abdominal discomfort in the days following the procedure. Rare but real complications have included duodenal stenosis (narrowing), which was treatable endoscopically in reported cases, and one reported case of bowel perforation related to endoscope manipulation. Longer-term data from a small cohort of 46 patients followed for two years showed no serious device-related adverse events, alongside a couple of cases of constipation and vitamin B12 deficiency possibly related to the altered duodenal lining. One reassuring biological detail: the duodenal mucosa fully regrows within about six weeks after the procedure, suggesting the treatment's benefit isn't due to any permanent structural change, but rather a genuine metabolic "reset" of the lining's signaling behavior.

Given where the evidence currently stands, DMR is best understood today as an emerging, still largely investigational option — appropriate primarily within research studies or specialized centers, generally being explored for patients roughly age 28 to 75, with type 2 diabetes, HbA1c between 7.5% and 10%, and BMI between 24 and 40 kg/m², with reasonably preserved insulin production. It is not appropriate for patients with type 1 diabetes, prior GI surgery that would prevent duodenal access, a history of pancreatitis, or those on active anticoagulant therapy.

My honest advice to patients who ask about this: DMR is one of the more scientifically interesting developments in endoscopic metabolic therapy in recent years, but it remains, in the researchers' own words, "an emerging and, to some extent, experimental procedure." The field genuinely lacks long-term data beyond two years and head-to-head comparisons between the different DMR techniques. For now, our well-established endoscopic and surgical options — balloons, ESG, and bariatric surgery — remain the primary tools I recommend, with DMR best pursued through a formal clinical trial for appropriately selected patients, particularly those working to reduce insulin dependence alongside GLP-1 therapy. I expect this to be an area worth revisiting in a year or two, as more mature data becomes available.

Source: Review of endoscopic duodenal mucosal resurfacing techniques and outcomes, Practical Gastroenterology, 2026, and associated clinical literature on hydrothermal DMR, laser duodenal ablation, and irreversible electroporation for type 2 diabetes and MASLD.